Revisiting the Role of Adjuvant Radiotherapy in Non-Small Cell Lung Cancer
DOI:
https://doi.org/10.82582/thorac.74Keywords:
Carcinoma, Non-Small-Cell Lung, Radiotherapy, AdjuvantAbstract
.
Downloads
References
PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet. 1998;352:257-63. doi:10.1016/S0140-6736(98)06341-7
Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA, et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the ANITA Randomized Trial. Int J Radiat Oncol Biol Phys. 2008;72:695-701. doi:10.1016/j.ijrobp.2008.01.044
Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and mediastinal N2 involvement (LungART): an open-label, randomized, phase 3 trial. Lancet Oncol. 2022;23104-14. doi: 10.1016/S1470-2045(21)00606-9
Moulkasse Y, Pourel N, Lerouge D, Falvre-Finn C, Ramella S, Edwards J, et al. PH-0280: Quality of surgery and RT in stage IIIN2 NSCLC: Insights from the Lung Adjuvant Radiotherapy trial. Radiother Oncol. 2020;15:25440-1.
Feng QF, Wang M, Wang LJ, Yang ZY, Zhang ZM, Zheng L, et al. A randomized controlled trial of postoperative radiotherapy for pathologic N2 non-small cell lung cancer. J Thorac Oncol. 2022;17:987-96. doi:10.1016/j.jtho.2022.02.011
Chun SG, Hu C, Choy H, Komaki RU, Timmerman RD, Schild SE, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35:56-62. doi:10.1200/JCC.2016.691378
Oda N, Yamamoto N, Kawaguchi K, Fukui T, Nakamura S, Mitsudomi T. Extranodal extension is a significant prognostic factor in pathologic N2 non-small cell lung cancer. Ann Thorac Surg. 2020;109:258-64. doi:10.1016/j.athoracsur.2019.07.067
Daly ME, Singh N, Ismaila N, Antonoff MB, Arenberg DA, Bradley J, et al. Adjuvant systemic therapy and adjuvant radiation therapy for stage I to IIIA completely resected non-small-cell lung cancers: ASCO guideline rapid recommendation update. J Clin Oncol. 2021;391:213-6. doi:10.1200/JCC.2018.2723
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 5.2021. [accessed Dec 2024] Available at: http://www.nccn.org
Forde PM, Spicer J, Lu S, Provercio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973-85. doi:10.1056/NEJMoa2202170
Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7:1394-403. doi:10.1158/2159-8290.CD-17-0716
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Author(s) (or their employer(s)) and THORAC 2024
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
